Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Aug 06, 2018 9:56pm
114 Views
Post# 28419197

PMN has its fingers in this research aswell

PMN has its fingers in this research aswell

People living with Down syndrome could hold key to Alzheimer's disease

 
 SHOW TRANSCRIPT
 

Allie Tarzwell has a photo album full of good times. She's been to Tennessee, Texas, Disneyworld, the race track, even swimming with dolphins. She also won gold and silver medals at the Special Olympics.

It's been an adventure for her mother, Gayle, too. But with all the joy comes worry. 

Advertisement

Forty percent of people with Down syndrome develop Alzheimer's disease by age 40. That number increases to 50 percent by age 50.

Today, Allie is 32.

"It's coming at us fast is how I look at it," Gayle Tarzwell said. 

Dr. Brian Skotko knows the numbers. He's the director of the Down syndrome program at Massachusetts General Hospital.

"There's an urgency because they love their person with Down syndrome so much that they don't want to lose any of that. They don't want that personality to be lost to Alzheimer's," Skotko said. 

Skotko's patients have three copies of chromosome 21, the same chromosome linked to a build-up of sticky proteins or plaques that can lead to Alzheimer's. People without Down syndrome have just two.

"When people with Down syndrome have an extra copy, they build up those plaques faster," Skotko said.

The first symptoms often involve changes in behavior. People with Down syndrome can become irritated and depressed. Some experience seizures. The memory loss associated with Alzheimer's occurs later but it's just as devastating.

"So it's really prevalent in our population and it's a pressing concern because right now, we have no treatments for Alzheimer's itself. I think what we can learn from people with Down syndrome can help all of us," Skotko said. 

Allie is now part of a national clinical trial to test the safety of a new vaccine that may activate a patient's immune system to attack the plaques before they build up. Patients in the trial receive seven shots in one year and won't know if they're getting the vaccine or a placebo.

Allie and her mother say the decision to sign up was easy.

"We just knew we had to help out. Had to be part of the solution, not just for us but for other people out there that are at risk of having Alzheimer's disease, whether they have Down syndrome or not," Gayle Tarzwell said.


Bullboard Posts